CA3094104A1 - Procedes de determination du dosage d'un agent therapeutique en se basant sur les niveaux mesures d'un metabolite - Google Patents

Procedes de determination du dosage d'un agent therapeutique en se basant sur les niveaux mesures d'un metabolite Download PDF

Info

Publication number
CA3094104A1
CA3094104A1 CA3094104A CA3094104A CA3094104A1 CA 3094104 A1 CA3094104 A1 CA 3094104A1 CA 3094104 A CA3094104 A CA 3094104A CA 3094104 A CA3094104 A CA 3094104A CA 3094104 A1 CA3094104 A1 CA 3094104A1
Authority
CA
Canada
Prior art keywords
brequinar
subject
dose
agent
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3094104A
Other languages
English (en)
Inventor
Vikram S. Kumar
David P. Hesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clear Creek Bio Inc
Original Assignee
Clear Creek Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clear Creek Bio Inc filed Critical Clear Creek Bio Inc
Publication of CA3094104A1 publication Critical patent/CA3094104A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

L'invention concerne des procédés de détermination d'une dose thérapeutiquement efficace d'un agent qui cible une voie métabolique en se basant sur les niveaux mesurés d'un métabolite dans la voie. Les procédés, qui peuvent comprendre la fourniture de l'agent dans une dose thérapeutiquement efficace, sont utiles pour le traitement de troubles tels que le cancer chez un sujet. L'invention concerne également des procédés d'évaluation de l'impact d'un agent thérapeutique sur une tumeur chez un sujet par surveillance en temps réel du métabolisme d'une molécule dans la tumeur, l'oxygénation de la tumeur, ou les deux. L'invention concerne en outre des dispositifs qui déterminent une dose thérapeutiquement efficace d'un agent qui cible une voie métabolique en se basant sur les niveaux mesurés d'un métabolite dans la voie et notifient un sujet d'administrer la dose.
CA3094104A 2018-03-26 2019-03-26 Procedes de determination du dosage d'un agent therapeutique en se basant sur les niveaux mesures d'un metabolite Abandoned CA3094104A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862648320P 2018-03-26 2018-03-26
US62/648,320 2018-03-26
US201862655407P 2018-04-10 2018-04-10
US62/655,407 2018-04-10
US201862682427P 2018-06-08 2018-06-08
US201862682411P 2018-06-08 2018-06-08
US201862682419P 2018-06-08 2018-06-08
US62/682,411 2018-06-08
US62/682,427 2018-06-08
US62/682,419 2018-06-08
PCT/US2019/023983 WO2019191030A1 (fr) 2018-03-26 2019-03-26 Procédés de détermination du dosage d'un agent thérapeutique en se basant sur les niveaux mesurés d'un métabolite

Publications (1)

Publication Number Publication Date
CA3094104A1 true CA3094104A1 (fr) 2019-10-03

Family

ID=68058448

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3094104A Abandoned CA3094104A1 (fr) 2018-03-26 2019-03-26 Procedes de determination du dosage d'un agent therapeutique en se basant sur les niveaux mesures d'un metabolite

Country Status (5)

Country Link
EP (1) EP3773523A4 (fr)
JP (1) JP2021519338A (fr)
AU (1) AU2019242626A1 (fr)
CA (1) CA3094104A1 (fr)
WO (1) WO2019191030A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12012383B2 (en) 2018-03-26 2024-06-18 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
CA3169718A1 (fr) * 2020-03-18 2021-09-23 Reid M. Rubsamen Formulation injectable de microspheres d'acide poly(lactique-co-glycolique) (plga) encapsulant du siltuximab

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074633A2 (fr) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions et procédés permettant de caractériser, de réguler, de diagnostiquer et de traiter des cancers
CA2996632C (fr) * 2015-09-01 2023-10-17 Bayer Pharma Aktiengesellschaft Composes et methodes utiles pour le traitement ou la prevention de cancers hematologiques
EP3664803A4 (fr) * 2017-08-01 2021-05-05 PTC Therapeutics, Inc. Inhibiteur de dhodh pour utilisation dans le traitement de cancers hématologiques

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12012383B2 (en) 2018-03-26 2024-06-18 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase

Also Published As

Publication number Publication date
WO2019191030A1 (fr) 2019-10-03
JP2021519338A (ja) 2021-08-10
AU2019242626A1 (en) 2020-09-24
EP3773523A1 (fr) 2021-02-17
EP3773523A4 (fr) 2021-12-29

Similar Documents

Publication Publication Date Title
US20210154186A1 (en) Compositions and methods for inhibiting dihydroorotate dehydrogenase
CN110536703B (zh) 使用抗axl抗体-药物缀合物的组合疗法
CN107921050A (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
JP2020517652A5 (fr)
WO2020210418A1 (fr) Procédés de traitement d'un lymphome non hodgkinien à l'aide de la 2-(2,6-dioxopipéridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazétidin-1-yl)méthyl)benzyl)amino)isoindoline-1,3-dione
CA3094104A1 (fr) Procedes de determination du dosage d'un agent therapeutique en se basant sur les niveaux mesures d'un metabolite
KR20210151945A (ko) 대식세포 활성을 조정하기 위한 방법
US20210315880A1 (en) Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
JP2024028988A (ja) ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法
KR20200112904A (ko) 암을 치료하는 조성물 및 방법
US20190290892A1 (en) Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite
US20190290635A1 (en) Methods of treating brain cancer using agents that alter activity of a metabolic pathway
WO2022125829A1 (fr) Traitements contre le cancer du sein triple négatif avancé et/ou métastatique
JP2024524461A (ja) 進行性および／または転移性ｔｒｏｐ－２過剰発現ガンを有する治療困難患者における併用治療
KR20200061382A (ko) 암을 치료하기 위한 조성물 및 방법
AU2022263424A1 (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230928